Design, synthesis, molecular docking, and anticancer evaluations of 1benzylquinazoline2,4(1H,3H)‐dione bearing different moieties as VEGFR2 inhibitors

K El‐Adl, AGA El‐Helby, H Sakr… - Archiv der …, 2020 - Wiley Online Library
… to obtain more potent VEGFR-2 inhibitors, the goal of our work was the synthesis of new …
used VEGFR-2 inhibitors (eg, sorafenib). The main core of our molecular design rationale …

Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations

AA Mohamed, SSA El-Hddad, AKB Aljohani… - Bioorganic …, 2024 - Elsevier
… and different moieties as EGFR, VEGFR-2 inhibitors and anticancer agents. We … a
series of new 6-iodoquinazolinone bearing different moieties with acetamide linker as …

Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies

M Moradi, A Mousavi, Z Emamgholipour… - European Journal of …, 2023 - Elsevier
… , which are one of the most identified targets in anti-cancer … core and aniline moiety showed
VEGFR-2 selectivity in this … Compounds bearing bulky halogen atoms on aniline moiety

[HTML][HTML] Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

M Alsulaimany, K El-Adl, AKB Aljohani, HY Alharbi… - RSC …, 2023 - pubs.rsc.org
… and different moieties as EGFR, VEGFR-2 inhibitors and … a series of new 6-iodoquinazolinone
bearing different moieties … In silico molecular modeling study was performed for our …

Novel 4-(piperazin-1-yl) quinolin-2 (1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition

A Hassan, M Badr, HA Hassan, D Abdelhamid… - Bioorganic & Medicinal …, 2021 - Elsevier
anticancer medications in last two decades are TK inhibitors … impact of 4-phenylthiazole
moiety on anticancer activity of … VEGFR-2 inhibiting effect and molecular modeling of newly …

… [3, 4-d] pyrimidine derivatives as EGFRT790M and VEGFR-2 dual TK inhibitors: Design, synthesis, molecular docking, ADMET profile and anticancer evaluations

D Adel, K El-Adl, T Nasr, TM Sakr, W Zaghary - Journal of Molecular …, 2023 - Elsevier
moiety were higher than those of the other derivatives against MCF-7, HCT116, and A549
but were less effective against HepG2. Derivative 15 with the oxadiazole-5-thiol moiety had …

[HTML][HTML] … as dual EGFR T790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations

KE Anwer, SSA El-Hddad, NEA Abd El-Sattar… - RSC …, 2023 - pubs.rsc.org
moieties were designed and synthesized according to the essential VEGFR-2 inhibitors
for anticancer treatment. Four key characteristics were found to be shared by sorafenib and …

[HTML][HTML] Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR WT and EGFR T790M: design, synthesis, ADMET …

AKB Aljohani, K El-Adl, B Almohaywi, OM Alatawi… - RSC …, 2024 - pubs.rsc.org
… 14b, 16 and 18 excellently inhibited VEGFR-2 activity with IC 50 … and different moieties to
produce anticancer agents targeting … of 6-iodo-1-benzylquinazoline-2,4(1H,3H)-dione (12) with …

… hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition

Y El-Dash, E Elzayat, AM Abdou, RA Hassan - Bioorganic Chemistry, 2021 - Elsevier
moieties were designed and evaluated for their anticancer activity. … of 4-chlorophenyl
cycloalkylthieno[2,3-d]pyrimidines bearing … , the molecular modeling studies were carried out …

… , synthesis, molecular docking and anti-proliferative evaluations of [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors

K El-Adl, AGA El-Helby, H Sakr, A Elwan - Bioorganic Chemistry, 2020 - Elsevier
… which attached to the distal moieties. The data obtained revealed that… ,4]triazolo[4,3-a]quinoxaline
based derivatives have been designed, synthesized and evaluated for their anticancer